IKONISYS - Investor website
  • Français (France)
  • English (United Kingdom)
  • Welcome
  • Press releases
  • Documentation
    • Documentation
    • Corporate Presentation
    • Universal registration document
    • Financial report
    • Financial operations
    • Regulated information
      • Shares and voting rights
      • Liquidity contract
      • OCABSA
      • Directors' disclosure
      • Governance
  • Shareholders
    • Shareholders
    • General meeting
      • Extraordinary General Meeting October 06, 2022
      • General Meeting of June 16, 2022
    • Shareholding structure
    • Financial calendar
    • Stock information
    • Analyst coverage
  • Contacts
 

Press releases

All years
2023
2022
2021
  • 02/01/2023 - 11:15

    Ikonisys and Integrated Gulf Biosystems Group enter into Distribution Collaboration for Distribution of the Ikoniscope20 System in the Middle East Market

  • 11/14/2022 - 18:28

    Ikonisys announces the launch of its instrument for high-volume customers, the Ikoniscope20max

  • 10/27/2022 - 17:45

    Ikonisys publishes its 2022 half-year financial results and reviews its operational deployments

  • 10/05/2022 - 23:19

    Ikonisys has signed a financing agreement of up to €5.1m of aggregate principal amount to continue its commercial and development strategy and has drawn down a first tranche

  • 09/26/2022 - 18:00

    Ikonisys announces the installation of the Ikoniscope20 solution at a US leading urology laboratory

  • 09/21/2022 - 14:19

    Ikonisys and Negma Group announce the end of their financing agreement

  • 09/13/2022 - 18:47

    Ikonisys announces the start of a Distribution Collaboration with BioVendor Laboratory Medicine for Distribution of the Ikoniscope20 System in the Eastern European Market

  • 07/26/2022 - 18:00

    Ikonisys reinforces its strategic collaboration with Empire Genomics following excellent results of optimized reagents in detection of bladder cancer cells

  • 06/22/2022 - 18:00

    Ikonisys announces the first sale of the Ikoniscope20 solution including the newly added reagents to Comprehensive Urology

  • 05/24/2022 - 18:00

    Ikonisys signs contract and initiates research activities with Politecnico di Milano, a world leading public scientific-technological university in the field of computer science and bioengineering

  • 05/12/2022 - 18:30

    Ikonisys Partners With Evosciences Leasing To Support The Commercial Expansion In Europe And The Usa Of The Ikoniscope20

  • 05/04/2022 - 23:00

    Ikonisys has signed a financing agreement of up to €6m of aggregate nominal amount to continue the commercial roll-out map

  • 04/29/2022 - 20:00

    Ikonisys publishes its Full-Year Financial Results for 2021 and provides an update on its latest developments

  • 03/29/2022 - 17:45

    Ikonisys announces its participation in the Investor Access forum

  • 02/16/2022 - 18:30

    The Ikoniscope20 preliminary results obtained with University of Connecticut School of Medicine (Neag Cancer Center of UConn) in detecting rare cells surpass the standards of test in immuno-oncology

  • 02/07/2022 - 18:45

    Ikonisys announces the successfull installation of the Ikoniscope20 at Tomalab, one of the largest genetic laboratories in Italy

  • 02/01/2022 - 18:00

    Ikonisys SA announces the appointment of Gabriel Plan as France sales Director

  • 01/26/2022 - 18:30

    Ikonisys announces the initation of coverage of its stock by Sphene Capital

  • 10/29/2021 - 18:00

    Ikonisys publishes its half-year financial results for 2021 and provides an update on its developments since its IPO

  • 09/30/2021 - 17:45

    Ikonisys sa welcomes us sales director, accelerating its growth and expansion plans in the usa

  • 09/06/2021 - 17:45

    Initial results of a study, in collaboration with the uconn school of medicine, highlight the potential of ikonisys’ cell-based diagnostic platform in immuno-oncology

  • 09/06/2021 - 17:45

    Initial results of a study, in collaboration with the uconn school of medicine, highlight the potential of ikonisys’ cell-based diagnostic platform in immuno-oncology

  • 07/13/2021 - 19:30

    Succes of Ikonisys' initial public offering on Euronext Growth® Paris

  • © Ikonisys 2023 - All rights reserved
  • Mentions légales - Legal notice
Ask us your questions Suscribe to the Newsletter
Z3333